

SARTORIUS

Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech

SARTORIUS

Opening of the meeting

Dr. Michael Grosse, Chairman of the Board of Directors

Michael Grosse

Ratification of the co-optation as a Director

Professional Experience

Various management and board positions in the packaging industry for the pharmaceutical and food sector over the past 20 years

Education

- Dr. Ing./PhD, Mechanical Engineering
- Dipl. Ing./ Master, Mechanical Engineering
- Business Administration

Core Competencies

- Strategy development, portfolio management, M&A
- Technology and product development
- Human Resources & IT



Year of Birth: 1967
Nationality: German

Agenda

01 Ordinary Shareholders' Meeting

- Reading of the reports of the Board of Directors
- Reading of the reports of the Statutory Auditors
- Resolutions Nos. 1–12

02 Extraordinary Shareholders' Meeting

- Reading of the Report of the Board of Directors
- Reading of the Special Reports of the Statutory Auditors
- Resolutions Nos. 13–15

SARTORIUS


Report of the CEO

Dr. René Fáber


Sartorius continues profitable
growth path

Strong profitable growth driven by consumables demand

Sales revenue | € in millions




UI. EBITDA & margin | € in millions




Dividend proposal

Underlying earnings per share in €



Dividend per share in €



Ongoing investments in innovation, growth and resilience



Songdo, South Korea
Sterile consumables, labs

Aubagne, France
Sterile disposable bags, office space


Bielefeld, Germany
Media

Göttingen, Germany
Membrane and filter

Freiburg, Germany
Cell culture components

€393 million
Capex

13.3%
Capex ratio




Sustainability certifications enable the use of renewable materials and pave the way for more sustainable products



ISCC PLUS certification for four sites

- Certified production network includes Göttingen (Germany), Aubagne (France), M'Hamdia (Tunisia) and Stonehouse (UK)
- Use of bio-circular raw materials significantly reduces the share of fossil-based plastics
- Product offering now includes single-use bags, filters and laboratory-scale bioreactors
- Certification of additional sites planned

An ambitious team of more than 10,250 people



96 Nationalities


54% Younger than 40 years

74% Internal management hires

35% Women in leadership

What we are building on

Anchored in purpose – Ambitious to shape the future



Our Purpose	Better health for more people.	
Our Mission	We empower biopharma customers to accelerate drug development and enhance manufacturing efficiency for better therapies and more affordable medicine.	
Our Promise	Simplifying Progress	



A leading biologics pure play with unique strengths in single-use

 Strong focus on biopharma	Highly differentiated end-to-end portfolio; leading market positions
 Unique know-how	Deep scientific, application and regulatory expertise
 Trusted supplier	Superior and consistent quality and global technical support
 Global footprint	Strong presence in all regions, resilient supply chains
 Long-term partnerships	With scientific research institutions, universities, and customers

Compelling business profile in a ten years perspective



A scalable single-use platform for efficient biopharma manufacturing

 **Our ambition**
More efficient bioprocessing

 Scalable end-to-end solutions for all biopharmaceutical modalities;
Market leader in single-use technologies

Design safe and flexible processes

Reduce investments

Increase productivity

Enhance product yield

Media & reagents



Bioreactors



Chromatography



Filtration



Fluid management



Digital solutions



Note: Highlighted products are a sample from our end-to-end portfolio

Attractive business model with high share of recurring revenue

Steady recurring revenues supported by validated manufacturing processes and equipment installations



~85%
Recurring revenue

FY 2025 figures

Strong market fundamentals


Sustained strong market fundamentals



Growing and aging population¹

>1.6bn


Estimated number of people aged 65+ by 2050 (2x vs 2025)



Growing pharma market²

~10% p.a.

(vs. ~5% for total pharma market)



Shift in medicine to biologics²

~57%

share of biologics in pharma market 2030e (+~22pp vs 2015)



Well-filled R&D pipeline^{2,3}

~26,000

number of drug candidates in development

Sources: 1 WHO 2 Evaluate Pharma, April 2025, GloblaData , January 2026 3 Sartorius market intelligence

R&D and production volumes as structural market growth drivers


Addressable market
CAGR mid-term¹

8-10%



Opportunities

- Biopharma R&D and production volumes continue to grow, driven by expanding pipelines, drug approvals, and rising patient demand
- Increasing complexity and diversity of modalities drive investment in technological innovation
- AI and technology are accelerating the pace of change



Challenges

- Pressure on healthcare systems and drug pricing
- Geopolitical dynamics and policy shifts add complexity and friction

Source: Global Data, IQVIA, Market Reports & Sartorius Market Intelligence January 2026

How we shape the future

Strengthening Sartorius Stedim Biotech's competitive edge

Financial ambition

Profitable growth above market, enhanced cash generation, reduced leverage

Strategic initiatives

Portfolio

How to add value to customers

Focus on innovation, core strengths and emerging opportunities

Customer experience

How to engage with customers

Trusted partnership, fast and reliable technical support and high service quality

Excellence & efficiency

How to operate

More cost-efficient, digital, automated and lean to provide short lead-times and high delivery reliability

Enablers

People engagement & culture

AI, data and digitalization

Empowerment

Sharpening portfolio for above-market growth



Our Goal

We stay focused on biopharma customers' workflows and strengthen our positioning through continued innovation leadership

Grow the core

Grow ambitiously and expand market leadership in our core businesses



Expanding into future businesses


Establish leading positions in emerging fields and technologies

Driving growth across the core and beyond


Core business



Process Intensification



Pionic



Ambr

Future businesses




ATS¹




Critical raw materials




Eveo



Core Single Use Technologies




Sartopore Evo




Celsius Pak



PAT & AC/QC²



Octet R8e



Sensors

1 Advanced Therapy Solutions 2 PAT = Process Analytical Technology, AC/QC = Analytical Characterization & Quality Control

Enhancing customer experience across the end-to-end journey

Customer expectations across the life science industry



Short lead times, convenient product customization



Reliable delivery and high-quality products




Simplified ordering and service workflows




Comprehensive & accessible online solutions

Initiatives to enhance customer experience

Improving lead times, delivery performance and configurability of our product to enhance customer value.



More automated and digitalized customer journey including self-service platforms, proactive messaging and predictive relevance to our customers



Evolving into a more cost-efficient, digitalized and lean organization



Operations transformation to achieve best-in-class supply chain performance, product and service quality

<p>Factory of the future</p> <p>more automation, digital tools, data-driven quality, fewer manual steps</p>	<p>Network optimization</p> <p>resilient and efficient global production footprint</p>	<p>Simplify operations</p> <p>clearer flows, less duplication, more standardization</p>	<p>Strengthen sourcing</p> <p>reduce risk, improve availability and cost positions</p>
--	---	--	---

AI and digital capabilities as the foundation for next-level operational excellence



Delivering an attractive
financial profile

Confident outlook 2026

Guidance 2026	Sales revenue growth ¹	Underlying EBITDA margin
Sartorius Stedim Biotech Group	~6% to ~10%	Slightly above 31%

- Sales growth includes ~1pp contribution from US tariff-related surcharges
- Capex ratio at ~PY level
- Net debt/ul. EBITDA to decrease to slightly above 2x

Due to the continued high dynamics and volatility across the life science industry, the forecast remains subject to greater uncertainty, which is reflected in the current guidance range. Potential additional U.S. tariffs are likewise not included.

¹ In constant currencies

Sustained outperformance supported by market trends

Sartorius Stedim Biotech mid-term ambition²

Addressable market CAGR mid-term ¹	Key drivers of outperformance	Above-market growth p.a.	Organic sales revenue growth p.a. in cc	ul EBITDA margin expansion p.a.	
8-10%	<ul style="list-style-type: none"> ▪ Leadership in SU and process intensification ▪ Unique advanced therapies portfolio 	+100-200bps	>	9-12%	~60-85bps

1 Sartorius market intelligence 2 starting as of 2027

Sustainable value creation remains well on track



Addressing attractive biopharma end markets with strong structural growth drivers



Biologics pure-play with focus on single-use; sticky business model with high share of recurring revenue



Strong focus on innovation leadership in relevant applications



Clear roadmap to leverage the core and expand future growth platforms



Initiatives for best-in-class customer experience and operational excellence



Continue above-market growth in the mid-term, margin expansion and improved cash generation

Thank you for your attention